^
Association details:
| Biomarker: | BIRC3 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | DC-1-192 (NF-κB inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-?B activity and synergise with bortezomib and ibrutinib in hematological cancers
Published date:
04/01/2021
Excerpt:
In primary CLL cells, sensitivity to DC-1-192 was inversely correlated with RelA subunit expression (r2=0.2) and samples with BIRC3 or NOTCH1 mutations showed increased sensitivity (P=0.001).
DOI:
10.3324/haematol.2019.238584
